(NASDAQ: LUMO) Lumos Pharma's forecast annual revenue growth rate of 209.65% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Lumos Pharma's revenue in 2024 is $1,525,000.On average, 2 Wall Street analysts forecast LUMO's revenue for 2024 to be $171,460,809, with the lowest LUMO revenue forecast at $16,638,800, and the highest LUMO revenue forecast at $326,282,818. On average, 2 Wall Street analysts forecast LUMO's revenue for 2025 to be $167,159,070, with the lowest LUMO revenue forecast at $16,638,800, and the highest LUMO revenue forecast at $317,679,340.
In 2026, LUMO is forecast to generate $408,421,676 in revenue, with the lowest revenue forecast at $16,638,800 and the highest revenue forecast at $800,204,552.